Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q2 FY27 Earnings Presentation
33 slides from Advanced Enzyme Technologies's earnings presentation, Oct 31, 2026
Slide 1: Exchange filing cover letter: Earnings Presentation
/ ic/ vancecl Enzymes Whore ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH 1989PLC051018 Sun Magnetica, A wing, 5th Floor, LIC Service Road, Louiswadi, Thane ( W ) -400 604, India Tel: + 91-22-4170 3200, Fax: + 91 -22-2583 5159 Email: info@advancedenzymes.com, www.advancedenzymes.com
Slide 2: Advanced Enzyme Technologies Limited Earnings Presentation
^ Kfranced enzymes Where ENZYME is Life Advanced Enzyme Technologies Limited Earnings Presentation October 2026
Slide 3: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words “believe,” “expect,” “an
Slide 4: Table of Contents
Advanced enzymes Where ENZYME is Life Performance Business 01 Summary | Q2 FY27 | Page 04 02 Performance | Page 07 Geographical Result 03 Performance | Page 11 04 Summary | Q2 FY27 | Page 12 Unique Focus Area 05 Investment Case | Page 26 06 Going Ahead | Page 29 TABLE OF 07 Shareholders’ Information
Slide 5: Results Summary – Q2 FY27 (Consolidated) Y-o-Y
f * % t Results Summary – Q2 FY27 (Consolidated) Y-o-Y / advanced enzymes Where ENZYME is Life Revenue (` mn) EBITDA (` mn) PAT (` mn) 2,145 721 512 1,845 601 447 16% 4 20% 4 14% Q2 FY26 I Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 S Revenue grew by 16% on y-o-y basis to EBITDA grew by 20% to ₹ 721 mil
Slide 6: Results Summary – Q2 FY27 (Consolidated) Q-o-Q
f / * /y Results Summary – Q2 FY27 (Consolidated) Q-o-Q / advanced enzymes Where ENZYME is Life Revenue (` mn) EBITDA (` mn) PAT (` mn) 2,145 721 512 1,917 12% 36% 529 33% 386 * %' V Q1 FY27 iQ2 FY27 Q1 FY27 i Q2 FY27 i Q1 FY27 Q2 FY27 Revenue grew by 12% on q-o-q basis to EBITDA grew by 36% to ₹ 72
Slide 7: Results Summary – H1 FY27 (Consolidated) YTD
f * % t Results Summary – H1 FY27 (Consolidated) YTD / advanced enzymes Where ENZYME is Life Revenue (` mn) EBITDA (` mn) PAT (` mn) 4,062 1,250 3,704 1,165 897 852 10% 4 7% 4 5% H1 FY26 I H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 S Revenue grew by 10% on YTD basis to ₹ 4,062 EBITDA grew by 7% to ₹ 1,
Slide 8: Human Nutrition
Human Nutrition \ ^^ /anceri enzymes Whore ENZYME is Life, (₹ in Million) 2^ 'j / Q2 FY27 Q2 FY26 H1 FY27 H1 FY26 60% +6% +0.4% 60% of Sales 1,285 1,212 2,443 2,434 of Sales Commentary: 1,281 1,285 1,221 1,212 • The human nutrition segment contributed around 60% during the 1,158 quarter to the total
Slide 9: Animal Nutrition
Animal Nutrition ^ dvenced enzymes Where ENZYME is Life (₹ in Million) >> Q2 FY27 Q2 FY26 H1 FY27 H1 FY26 12% +37% +14% 13% of Sales 265 193 517 452 of Sales 1 % # •V % * • V Commentary: • The animal nutrition segment contributed around 12% during the 260 244 250 252 265 HIhill quarter to the total
Slide 10: Industrial Bio-processing
Industrial Bio-processing / advanced enzymesWhere ENZYME is Life (₹ in Million) Food 14% Q2 FY27: ₹305 Mn Q2 FY27 Q2 FY26 H1 FY27 H1 FY26 17% +43% +37% 17% Non-Food of Sales 365 255 671 491 of Sales 3% Q2 FY27: ₹60 Mn Commentary: 361 365 • The Industrial Bio-Processing segment contributed 17% during
Slide 11: Specialized Manufacturing
Specialized Manufacturing ^ HNanced enzymes Where ENZYME is Life - ~ L~ > (₹ in Million) * A Q2 FY27 Q2 FY26 H1 FY27 H1 FY26 11% +25% +32% 11% of Sales 231 185 431 327 of Sales I Commentary: 231 • This segment contributed about 11% during the quarter to the total 200 revenue from operations 185 180
Slide 12: Geographical performance
Geographical performance Q2 FY27 H1 FY27 ^ Manced enzymes When? ENZYME is Life Q2 FY27 1,110 H1 FY27 2,047 52% Q2 FY26 887 +25% 50% H1 FY26 1,886 +10% India Q2 FY27 579 H1 FY27 1,144 27% Q2 FY26 554 +4% 28% H1 FY26 1,119 +2% Americas Q2 FY27 104 H1 FY27 236 5% Q2 FY26 116 -10% 6% H1 FY26 208 +14% Eu
Slide 13: Profit & Loss (Consolidated) – Q2 FY27 & H1 FY27
Profit & Loss (Consolidated) – Q2 FY27 & H1 FY27 ^ Manced enzymes Where ENZYME is Lite (₹ in Million) Q2 FY27 Q1 FY27 Q2 FY26 Y-o-Y Q-o-Q H1 FY27 H1 FY26 Y-o-Y Particulars Un-Audited Audited Un-Audited (%) (%) Un-Audited Un-Audited (%) Income from Operations 2,145 1,917 1,845 16% 12% 4,062 3,704 10%
Slide 14: Result summary - FY26 (Consolidated) Y-o-Y
f / * /y Result summary - FY26 (Consolidated) Y-o-Y / advanced enzymes Where ENZYME is Life Revenue (` mn) EBITDA (` mn) PAT (` mn) u 7,458 2,291 1,736 6,369 1,944 1,340 17% 4 18% 4 30% * GROWTH GROWTH GROWTH w* FY25 Human HC FY26 Animal HC FY25 FY26 Bio Processing FY25 FY26 Specialized Manufacturin
Slide 15: Revenue Split – FY25 vs. FY26
Revenue Split – FY25 vs. FY26 advanced enzymes Whom ENZYME is Life FY25 FY26 8% 9% 16% 16% 12% 64% 13% 62% Human HC Animal HC Bio-Processing Specialised Manufacturing Human HC Animal HC Bio-Processing Specialized Manufacturing 3% 3% 9% 12% 5% 5% 46% 50% 30% 37% India Americas Europe Asia (ex-India)
Slide 16: Strong Financial Performance – FY26
Strong Financial Performance – FY26 samAzua paoutPAppy 3J!15/ 3I/UZN3 dJdU/n Revenue from Operations EBIDTA & EBIDTA Margin (%) 7,458 38% 2,500 40% 6,239 6,369 33% 31% 31% 29% 35% 5,294 5,406 2,000 30% 25% 1,500 EBIDTA 1 1,000 500 20% 15% 10% EBIDTA MARGIN 2,014 1,564 2,045 1,944 2,291 5% 0 0% FY 22
Slide 17: Strong Financial Performance – FY26
Strong Financial Performance – FY26 ^ Manced enzymes Where ENZYME is Life Net Working Capital (Days) Net Worth (` mn) 16,320 146 14,209 135 135 138 13,241 132 12,351 10,886 FY 22 FY 23 FY 24 FY 25 FY 26 FY 22 FY 23 FY 24 FY 25 FY 26 ROE (%) & ROCE (%) Net Debt to Equity 15.93% 0.02 0.02 13.03% 12.21
Slide 18: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) enzymes Where ENZYME is Life (₹ in Million) FY26 FY25 FY24 FY23 FY22 Particulars Audited Audited Audited Audited Audited Assets Property, plant and equipment 2,758 2,929 2,765 2,732 2,622 Capital work-in-progress 512 217 411 215 151 Intangible assets 469 523 479 550 609
Slide 19: Annexure
Annexure
Slide 20: Company Overview
Company Overview ^ Manced enzymes Where ENZYME is Lite Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nu
Slide 21: Advanced Enzyme Technologies Limited – A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star ^ Manced enzymes When? ENZYME is Life 9 7 1st 2nd 2nd R&D Units Manufacturing Units Indian enzyme Highest market Listed integrated India – 5 | USA – 1 | India - 8 | USA - 1 company share in India enzyme player globally Germany –1 68+ 400+ 7
Slide 22: Brief History and Evolution
Brief History and Evolution ^ Manced enzymes When? ENZYME is Life Advanced Biochemicals • Acquired 50% stake in ranked as the Acquired 51% SaiGanesh Enzytech largest domestic Acquired 100% stake in Solutions • Established Starya manufacturer of stake in evoxx SciTech • Acquired an labs for independe
Slide 23: Board of Directors
Board of Directors ^ Manced enzymes Whore ENZYME is Life # • Mr. Vasant Rathi Mr. Mukund Kabra Mr. Pramod Kasat Ms. Rasika Rathi Mr. Vinod Jajoo Promoter Chairman Whole-time Director Independent Director Non-Executive Director Independent Director and Non-Executive Director Mr. Sunny Sharma Mr. Niti
Slide 24: Management Team
Management Team enzymes Where ENZYME is Life # ' Mr. Beni Prasad Rauka Mr. Harshad Doshi Ms. Rasika Rathi Group - Chief Financial Officer CFO & COO – Advanced General Counsel / Vice President Enzymes, USA And Secretary – Advanced Enzymes, USA • • Ms. Martina Doering Mr. Michael Puls Mr. Sanjay Basan
Slide 25: How Big is the Opportunity?
How Big is the Opportunity? Global Probiotics Market Global Enzymes Market ^ Manced enzymes When? ENZYME is Life Animal Probiotics $1Bn Grow at a 7% Grow at a $16 Bn CAGR 14.12% CAGR 7.80% CY 2024-29 till 2029 $13Bn Human Probiotics $12Bn 93% $3.57Bn Competitive Scenario in the Global Enzymes and Pr
Slide 26: What we are Aiming in the Opportunity?
What we are Aiming in the Opportunity? ^ Manced enzymes Where ENZYME is Life AETL’s Current Share of Revenue Focus Opportunity Addressable market for CARG(%) Area Size AETL over next 5 years** over next 5 years FY26 FY25 Human Nutrition Pharma/API $ 80 mn $ 50 mn 6% $ 24.90 mn, 29% $ 18.04 mn, 24% P
Slide 27: What Makes AETL a Unique Investment Case?
What Makes AETL a Unique Investment Case? enzymes Where ENZYME is Lite C Strong Research & Development Capabilities r* N with High Entry Barriers J Specialized Business C Inherent Diversification in the Business Model /\ I M // J advanced enzymes \ Where ENZYME is Life ^ vv M o V o 3 Integrated Play
Slide 28: Integrated Player with Presence Across the Enzyme Value Chain
Integrated Player with Presence Across the Enzyme Value Chain ^ Manced enzymes Where ENZYME is Lite Research & Manufacturing Marketing & Development Distribution Earnings Presentation | October 2026 27
Slide 29: Specialized Business With High Entry Barriers
Specialized Business With High Entry Barriers ^ Manced enzymes Where ENZYME is Lite Technocrat Promoters Cumulative experience of 7+ decades in the global enzyme industry Sustained Research & Development Consistent Investment into R&D over the past 15+ years Manufacturing Expertise Specialized techn
Slide 30: Future Growth Drivers
Future Growth Drivers ^ Manced enzymes Where ENZYME is Life Continued Inorganic Investment in R&D Expansion • Identify Product gaps and Develop new • Acquisition of Key Technologies, Enzymes, Probiotics & Solutions thereof Competencies & Skill-sets which Enable Consolidation and/or Entry into New Ma
Slide 31: Focus Areas Going Ahead
Focus Areas Going Ahead enzymes Whore ENZYME is Life Animal Nutrition Bio-Catalysis • Continuing conduct trials and studies to bring newer • Developing bio catalysis for API manufacturers, and effective nutritional products, which may improve providing enzymatic based solutions that are target the e
Slide 32: Shareholders Information
Shareholders Information Stock Data Stock Chart ^ Manced enzymes When? ENZYME is Life Market Capitalization (₹) 31,689 mn Shares Outstanding 111.15 mn 325.80 281.60 Symbol (NSE/ BSE) ADVENZYMES / 540025 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Jul-26 Aug-26
Slide 33: Thank You
Advanced enzymes - Sawant ChowK Nitin^ Where ENZYME is Life Company .Junction l| | KajutNad ' ' Cs * /Mawan Tadka THANK YOU Jps Institute - AWS, jre &Google Cloud Co... jsiness Square t Pipeline ^ Sant ^^ / dvanced Enzyme Sun Crest ^ Dnyaneshwar Chowk Advanced Enzyme Technologies Limited Address: 5t
Advanced Enzyme Technologies — Q2 FY27 Earnings Presentation on 6ix